The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Microtubule destabilising agents: far more than just antimitotic anticancer drugs
Open accessAbstract
Vinca alkaloids have been approved as anticancer drugs for more than 50 years. They have been classified as cytotoxic chemotherapy drugs that act during cellular mitosis, enabling them to target fast growing cancer cells. With the evolution of cancer drug development there has been a shift towards new “targeted” therapies to avoid the side effects and general toxicities of “cytotoxic chemotherapies” such as the vinca alkaloids. Due to their original classification, many have overlooked the fact that vinca alkaloids, taxanes and related drugs do have a specific molecular target: tubulin. They continue to be some of the most effective anticancer drugs, perhaps because their actions upon the microtubule network extend far beyond the ability to halt cells in mitosis, and include the induction of apoptosis at all phases of the cell cycle. In this review, we highlight the numerous cellular consequences of disrupting microtubule dynamics, expanding the textbook knowledge of microtubule destabilising agents and providing novel opportunities for their use in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AP-1 as a regulator of cell life and death
Shaulian, E., & Karin, M. (2002) · Nature Cell Biology · doi:10.1038/ncb0502-e131 · Cited by 2,961
JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis
Lei, K., & Davis, R. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0438011100 · Cited by 1,068
Puthalakath, H., Huang, D. C. S., O’Reilly, L. A., King, S. M., & Strasser, A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80456-6 · Cited by 1,054
Southan, C., Sharman, J. L., Benson, H. E., Faccenda, E., Pawson, A. J., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1037 · Cited by 1,035
Yamamoto, K., Ichijo, H., & Korsmeyer, S. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8469 · Cited by 1,003
Control of microtubule organization and dynamics: Two ends in the limelight
Akhmanova, A., & Steinmetz, M. O. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4084 · Cited by 895
Gascoigne, K. E., & Taylor, S. S. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.07.002 · Cited by 832
An overview of tubulin inhibitors that interact with the colchicine binding site
Lu, Y., Chen, J., Xiao, M., Li, W., & Miller, D. D. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0828-z · Cited by 709
Death through a tragedy: mitotic catastrophe
Vakifahmetoglu, H., Olsson, M., & Zhivotovsky, B. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.47 · Cited by 700
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Del Gaizo Moore, V., Brown, J. R., Certo, M., Love, T. M., Novina, C. D., & Letai, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 608
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes
Alexander, S. P., Fabbro, D., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13354 · Cited by 604
Bcl2 is the guardian of microtubule integrity.
Haldar, S., Basu, A., & Croce, C. M. (1997) · PubMed · Cited by 599
Dancey, J. T., Deubelbeiss, K. A., Harker, L. A., & Finch, C. A. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108517 · Cited by 573
Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases
Bogoyevitch, M. A., & Kobe, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00025-06 · Cited by 573
Targeting Microtubules by Natural Agents for Cancer Therapy
Mukhtar, E., Adhami, V. M., & Mukhtar, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0791 · Cited by 565
THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.
JOHNSON, I. S., Jg, A., Gorman, M., & Jp, B. (1963) · PubMed · Cited by 564
JNK-Mediated BIM Phosphorylation Potentiates BAX-Dependent Apoptosis
Putcha, G. V., Le, S., Frank, S., Besirli, C. G., Clark, K., Chu, B., Alix, S., Youle, R. J., LaMarche, A., Maroney, A. C., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00355-6 · Cited by 518
Jordan, M. A., Kamath, K., Manna, T., Okouneva, T., Miller, H. P., Davis, C., Littlefield, B. A., & Wilson, L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0345 · Cited by 489
Microtubules, microtubule-interfering agents and apoptosis
Mollinedo, F., & Gajate, C. (2003) · Apoptosis · doi:10.1023/a:1025513106330 · Cited by 477
BCL2 family in DNA damage and cell cycle control
Zinkel, S., Gross, A., & Yang, E. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401987 · Cited by 474
Silverman, J. A., & Deitcher, S. R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2042-4 · Cited by 474
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 420
Bai, R. L., Paull, K. D., Herald, C. L., Malspeis, L., Pettit, G. R., & Hamel, E. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98491-7 · Cited by 379
Srivastava, R. K., Srivastava, A. R., Korsmeyer, S. J., Nesterova, M., Cho-Chung, Y. S., & Longo, D. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.6.3509 · Cited by 365
The proliferation rate paradox in antimitotic chemotherapy
Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0335 · Cited by 363
Wang, T.-H., Wang, H.-S., Ichijo, H., Giannakakou, P., Foster, J. S., Fojo, T., & Wimalasena, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.4928 · Cited by 353
Mitosis is not a key target of microtubule agents in patient tumors
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228 · Cited by 314
Vascular disrupting agents in clinical development
Hinnen, P., & Eskens, F. A. L. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603694 · Cited by 263
Regulation of microtubule stability and mitotic progression by survivin.
Giodini, A., Kallio, M. J., Wall, N. R., Gorbsky, G. J., Tognin, S., Marchisio, P. C., Symons, M. H., & Altieri, D. C. (2002) · PubMed · Cited by 256
Field, J. J., Kanakkanthara, A., & Miller, J. H. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.035 · Cited by 251
The Concise Guide to PHARMACOLOGY 2015/16: Overview
Alexander, S. P., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., Buneman, O. P., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13347 · Cited by 230
Multisite Phosphorylation Regulates Bim Stability and Apoptotic Activity
Hübner, A., Barrett, T., Flavell, R. A., & Davis, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.025 · Cited by 228
Komlodi-Pasztor, E., Sackett, D. L., & Fojo, A. T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0999 · Cited by 227
Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent
Dybdal-Hargreaves, N. F., Risinger, A. L., & Mooberry, S. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3252 · Cited by 225
Phosphorylation of Bcl-2 Is a Marker of M Phase Events and Not a Determinant of Apoptosis
Ling, Y.-H., Tornos, C., & Perez-Soler, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.18984 · Cited by 222
Antivascular Actions of Microtubule-Binding Drugs
Schwartz, E. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2710 · Cited by 218
Wang, T.-H., Popp, D. M., Wang, H.-S., Saitoh, M., Mural, J. G., Henley, D. C., Ichijo, H., & Wimalasena, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8208 · Cited by 216
Antibody–drug conjugates—A new wave of cancer drugs
Bouchard, H., Viskov, C., & Garcia-Echeverria, C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.10.021 · Cited by 190
The JIP family of MAPK scaffold proteins
Whitmarsh, A. J. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340828 · Cited by 168
Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells.
Haldar, S. M., Basu, A., & Croce, C. M. (1998) · PubMed · Cited by 166
Stone, A. A., & Chambers, T. C. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4731 · Cited by 166
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment
Correia, C., Lee, S.-H., Meng, X. W., Vincelette, N. D., Knorr, K. L. B., Ding, H., Nowakowski, G. S., Dai, H., & Kaufmann, S. H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.03.012 · Cited by 166
Zhang, C. C., Yang, J.-M., White, E., Murphy, M., Levine, A., & Hait, W. N. (1998) · Oncogene · doi:10.1038/sj.onc.1201658 · Cited by 159
Control of a Kinesin-Cargo Linkage Mechanism by JNK Pathway Kinases
Horiuchi, D., Collins, C. A., Bhat, P., Barkus, R. V., DiAntonio, A., & Saxton, W. M. (2007) · Current Biology · doi:10.1016/j.cub.2007.06.062 · Cited by 158
Shtil, A. A., Mandlekar, S., Yu, R., Walter, R. J., Hagen, K. L., Tan, T., Roninson, I. B., & Kong, A. T. (1999) · Oncogene · doi:10.1038/sj.onc.1202305 · Cited by 151
Du, L., Lyle, C. S., Obey, T. B., Gaarde, W. A., Muir, J. A., Bennett, B. L., & Chambers, T. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m304935200 · Cited by 147
Flynn, B. L., Gill, G. S., Grobelny, D. W., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200454y · Cited by 143
Brantley-Finley, C., Lyle, C. S., Du, L., Goodwin, M. E., Hall, T., Szwedo, D., Kaushal, G. P., & Chambers, T. C. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00255-7 · Cited by 139
The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells
Gawlik-Rzemieniewska, N., & Bednarek, I. A. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1121348 · Cited by 134
Bijman, M. N. A., Amerongen, G. P. V. N., Laurens, N., van Hinsbergh, V. W. M., & Boven, E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0242 · Cited by 122
Albershardt, T. C., Salerni, B. L., Soderquist, R. S., Bates, D. J. P., Pletnev, A. A., Kisselev, A. F., & Eastman, A. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.255828 · Cited by 115
Self-citationMicrotubule-targeted agents: When mitochondria become essential to chemotherapy
Rovini, A. M. F., Savry, A., Braguer, D., & Carré, M. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.01.001 · Cited by 108
Chiu, W. C., Luo, S.-J., Chen, C., Cheng, J., Hsieh, C.-Y., Wang, C., Huang, W., Su, W., & Lin, C. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.016 · Cited by 106
Phase II trial of dolastatin-10 in patients with advanced breast cancer
Perez, E. A., Hillman, D. W., Fishkin, P. A. S., Krook, J. E., Tan, W. W., Kuriakose, P., Alberts, S. R., & Dakhil, S. R. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-6735-y · Cited by 102
The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4
Su, M., Huang, J., Liu, S., Xiao, Y., Qin, X., Liu, J., Pi, C., Luo, T., Li, J., Chen, X., et al. (2016) · Scientific Reports · doi:10.1038/srep28139 · Cited by 86
Du, L., Lyle, C. S., & Chambers, T. C. (2004) · Oncogene · doi:10.1038/sj.onc.1208189 · Cited by 84
Hitting the brakes: targeting microtubule motors in cancer
Chandrasekaran, G., Tátrai, P., & Gergely, F. V. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.264 · Cited by 82
Combretastatins: More Than Just Vascular Targeting Agents?
Greene, L. M., Meegan, M. J., & Zisterer, D. M. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226225 · Cited by 81
Basu, A., & Haldar, S. M. (1998) · International Journal of Oncology · doi:10.3892/ijo.13.4.659 · Cited by 81
Tubulin: An Example of Targeted Chemotherapy
Seligmann, J. F., & Twelves, C. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.217 · Cited by 79
Cheung, C. H. A., Chen, H.-H., Kuo, C., Chang, C.-Y., Coumar, M. S., Hsieh, H., & Chang, J. Y. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-43 · Cited by 75
Gibson, S. B., Widmann, C., & Johnson, G. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10916 · Cited by 74
Kinesin-1 Regulates Microtubule Dynamics via a c-Jun N-terminal Kinase-dependent Mechanism
Daire, V., Giustiniani, J., Leroy-Gori, I., Quesnoit, M., Drevensek, S., Dimitrov, A., Perez, F., & Poüs, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.007906 · Cited by 72
Microtubule targeting agents: from biophysics to proteomics
Calligaris, D., Verdier‐Pinard, P., Devred, F., Villard, C., Braguer, D., & Lafitte, D. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0245-6 · Cited by 70
Petit, I., Karajannis, M. A., Vincent, L., Young, L. M., Butler, J. M., Hooper, A. T., Shido, K., Steller, H., Chaplin, D. J., Feldman, E. J., et al. (2007) · Blood · doi:10.1182/blood-2007-05-089219 · Cited by 65
Kolomeichuk, S. N., Terrano, D. T., Lyle, C. S., Sabapathy, K., & Chambers, T. C. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06349.x · Cited by 64
Stadheim, T. A., Xiao, H., & Eastman, A. R. (2001) · PubMed · Cited by 63
Self-citationPhase II trials of dolastatin-10 in advanced pancreaticobiliary cancers
Kindler, H. L., Tothy, P. K., Wolff, R. A., McCormack, R. A., Abbruzzese, J. L., Mani, S., Wade-Oliver, K. T., & Vokes, E. E. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-2909-x · Cited by 62
Mabeta, P., & Pepper, M. S. (2009) · Angiogenesis · doi:10.1007/s10456-009-9134-8 · Cited by 61
Rischin, D., Bibby, D. C., Chong, G., Kremmidiotis, G., Leske, A. F., Matthews, C. A., Wong, S., Rosen, M. A., & Desai, J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0937 · Cited by 61
Salerni, B. L., Bates, D. J. P., Albershardt, T. C., Lowrey, C. H., & Eastman, A. R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0028 · Cited by 60
Self-citationChamberlain, M. C., Grimm, S. A., Phuphanich, S., Recht, L. D., Zhu, J. Z. J., Kim, L., Rosenfeld, S., & Fadul, C. E. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1437-y · Cited by 59
Basu, A., DuBois, G., & Haldar, S. (2006) · Frontiers in bioscience · doi:10.2741/1900 · Cited by 52
Colin, D., Hain, K. O., Allan, L. A., & Clarke, P. R. (2015) · Open Biology · doi:10.1098/rsob.140156 · Cited by 51
Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate
Salmon, B. A., & Siemann, D. W. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.12.051 · Cited by 50
Ahmed, B., van Eijk, L. I., Steege, J. C. A. B.-T., van der Schaft, D. W. J., van Esch, A. M., Joosten-Achjanie, S., Lambin, P., Landuyt, W., & Griffioen, A. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11010 · Cited by 45
Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine
Upreti, M., Chu, R., Galitovskaya, E. N., Smart, S. K., & Chambers, T. C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2299 · Cited by 43
Potential Mechanisms of Resistance to Microtubule Inhibitors
Kavallaris, M., Annereau, J., & Barret, J.-M. M. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.01.006 · Cited by 41
Phase II Trial of Dolastatin‐10, a Novel Anti‐Tubulin Agent, in Metastatic Soft Tissue Sarcomas
von Mehren, M., Balcerzak, S. P., Kraft, A. S., Edmonson, J. H., Okuno, S. H., Davey, M., McLaughlin, S. B., Beard, M., & Rogatko, A. (2004) · Sarcoma · doi:10.1155/2004/924913 · Cited by 39
Fürst, R., & Vollmar, A. M. (2013) · Die Pharmazie · doi:10.31083/ph.2013.6509 · Cited by 38
Bates, D. J. P., Danilov, A. V., Lowrey, C. H., & Eastman, A. R. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1197 · Cited by 38
Self-citationActivation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells
Zhu, B.-K., Wang, P., Zhang, X. D., Jiang, C. C., Chen, L. H., Avery‐Kiejda, K. A., Watts, R. N., & Hersey, P. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f3138a · Cited by 34
Ehrhardt, H., Schrembs, D., Moritz, C., Wachter, F., Haldar, S., Graubner, U. B., Nathrath, M., & Jeremias, I. (2011) · Blood · doi:10.1182/blood-2010-02-269811 · Cited by 33
Han, C. R., Jun, D. Y., Lee, J. Y., & Kim, Y. H. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0928-1 · Cited by 33
von Pawel, J., Gorbounova, V. A., Reck, M., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.013 · Cited by 30
Eribulin: A Novel Cytotoxic Chemotherapy Agent
Preston, J. N., & Trivedi, M. V. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q636 · Cited by 28
Bates, D. J. P., Salerni, B. L., Lowrey, C. H., & Eastman, A. R. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.16909 · Cited by 26
Self-citationMuscarella, D. E., & Bloom, S. E. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.11.032 · Cited by 26
MEKK1 Is Essential for DT40 Cell Apoptosis in Response to Microtubule Disruption
Kwan, R., Burnside, J., Kurosaki, T., & Cheng, G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7183-7190.2001 · Cited by 26
Frezzato, F., Trimarco, V., Martini, V., Gattazzo, C., Ave, E., Visentin, A., Cabrelle, A., Olivieri, V., Zambello, R., Facco, M., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12815 · Cited by 26
Bates, D. J. P., Feris, E. J., Danilov, A. V., & Eastman, A. R. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139245 · Cited by 21
Self-citationChen, J., Sun, W., Wasylyk, B., Wang, Y., & Zheng, H. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834bc978 · Cited by 17
Isshiki, K., Hirase, T., Matsuda, S., Miyamoto, K., Tsuji, A., & Yuasa, K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.151 · Cited by 15
Kitchens, C. A., McDonald, P. R., Shun, T. Y., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.184879 · Cited by 15
Too early to say, “no targeting of mitosis!”
Kitagawa, K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228-c1 · Cited by 9
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Dhyani, P., Quispe, C., Sharma, E., Bahukhandi, A., Sati, P., Attri, D. C., Szopa, A., Sharifi-Rad, J., Docea, A. O., Mardare, I., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02624-9 · Cited by 483
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead
Martino, E., Casamassima, G., Castiglione, S., Cellupica, E., Pantalone, S., Papagni, F., Rui, M., Siciliano, A. M., & Collina, S. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.06.044 · Cited by 337
Metadata
- Authors
- Bates, D., & Eastman, A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2016-10-18
- Volume
- 83
- Issue
- 2
- Pages
- 255-268
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2523277769
- Cited by
- 298
- References
- 96
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.